Intellia Therapeutics Reports “Paradigm-Shifting” Phase 3 Data for Lonvoguran Ziclumeran, Achieving 87% Reduction in HAE Attacks with Single In Vivo CRISPR Dose

Fierce Biotech USA

Overview

Intellia Therapeutics announced groundbreaking Phase 3 HAELO trial data for lonvoguran ziclumeran (lonvo-z), an *in vivo* CRISPR gene-editing therapy for hereditary angioedema (HAE). This one-time treatment demonstrated a statistically and clinically significant 87% reduction in monthly HAE attack rates, with approximately two-thirds of treated patients achieving complete freedom from attacks without prophylactic medication. This marks the first successful Phase 3 trial for an *in vivo* CRISPR-based therapy, validating the technology’s potential for curative genetic disease treatment.

In Depth

Key Findings

Intellia Therapeutics has unveiled additional, highly positive Phase 3 data for its *in vivo* CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for patients with hereditary angioedema (HAE). This single-dose treatment achieved a dramatic 87% reduction in monthly HAE attack rates, meeting both primary and all secondary endpoints with statistical and clinical significance. This represents a “paradigm shift” in genetic disease treatment, as it is the first time an *in vivo* CRISPR gene-editing therapy has demonstrated success in a pivotal Phase 3 trial.

Technical / Clinical Details

• Compelling Efficacy: Lonvoguran ziclumeran is administered as a single intravenous infusion designed to permanently inactivate the *KLKB1* gene in liver cells, thereby preventing the overproduction of bradykinin, the underlying cause of HAE attacks. In the Phase 3 HAELO study, patients treated with lonvo-z experienced an average 87% reduction in monthly HAE attacks over a median follow-up of 12 months. Notably, approximately two-thirds of treated patients achieved complete freedom from attacks without requiring any additional prophylactic medication, a profound outcome compared to existing symptomatic or preventive treatments.
• Favorable Safety Profile: The reported safety data from the trial were robust, with no serious adverse events specifically attributed to lonvo-z in the treatment group. This favorable safety profile is critical for gene-editing therapies, addressing long-standing concerns about potential off-target effects or immunogenicity, and instilling confidence in the broader application of CRISPR-based treatments.
• Mechanism of Action: Lonvo-z utilizes the CRISPR-Cas9 system, delivered via lipid nanoparticles (LNPs), to precisely edit and inactivate the *KLKB1* gene within hepatocytes. By targeting the liver, a key site for kallikrein production, the therapy aims to provide a durable and potentially curative solution by addressing the root cause of the disease rather than merely managing symptoms.

Background & Context

Hereditary angioedema (HAE) is a rare, debilitating genetic disorder affecting approximately 1 in 3,500 male births worldwide. It is characterized by the absence or dysfunction of the dystrophin protein, leading to relentless muscle degeneration, eventually resulting in cardiac and respiratory failure. Current treatments are predominantly focus on symptom management or prophylaxis to reduce attack frequency, with no truly curative option available. Intellia’s successful Phase 3 outcome for lonvoguran ziclumeran marks a historic moment for the entire gene-editing field. This achievement underscores the maturation of CRISPR technology from a research tool to a tangible, life-changing therapeutic modality, validating years of scientific effort and investment in *in vivo* genome editing.

Strategic Significance & Outlook

Following these impressive Phase 3 results, Intellia Therapeutics is expected to file for regulatory approval with the FDA and other global agencies in the near future. Approval would provide HAE patients with a revolutionary, single-dose treatment option that could dramatically improve their lives. Furthermore, this success is anticipated to serve as a powerful catalyst for accelerated development of other *in vivo* CRISPR gene-editing therapies for a range of genetic diseases, potentially transforming the biopharmaceutical landscape. While long-term safety and durability data remain important areas for continued surveillance, this pioneering achievement ignites tremendous optimism for the future of gene therapy beyond rare diseases.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime